RxDoctor Payments Data

Savanna Jenks

Primary Care · Columbia, TNNPI 1801412887

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 99 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by AbbVie at 38.3% of the total.

$1,638in general payments, 2019–2025

Across 99 payments — averaging $16.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$628
  • Novo Nordisk$257
  • Lilly USA, LLC$161
  • Reapplix Inc.$93
  • AstraZeneca$87
  • Axsome Therapeutics, Inc.$79
  • plus $332 from 10 others

What the payments were for

  • Food & beverage$1,638100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,638 in reported general payments places this provider in the 70th percentile of 189 primary care providers in Tennessee.

See all primary care providers in Tennessee

Medicare billing

Part B allowed, 2024
$1,280
Medicare patients
13
Services billed
60

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide61$68,968
TrulicityDulaglutide14$24,738
JardianceEmpagliflozin16$19,287
EliquisApixaban18$17,856
MounjaroTirzepatide12$15,339
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$5,166
VyvanseLisdexamfetamine Dimesylate11$4,719
SymbicortBudesonide/Formoterol Fumarate15$3,625
Albuterol Sulfate HfaAlbuterol Sulfate65$1,561
Omeprazole45$1,170
Duloxetine Hcl16$783
Pregabalin25$747
Gabapentin81$722
Levothyroxine Sodium59$592
Atorvastatin Calcium64$493

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$257$68,96861 claims
Lilly USA, LLCTrulicity, Mounjaro$161$40,07726 claims
Boehringer IngelheimJardiance$52$19,28716 claims
PfizerEliquis$20$17,85618 claims
AstraZenecaSymbicort$87$3,62515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 189 primary care providers in Tennessee.

Other primary care in Columbia

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →